InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,011.12
(
-0.22%
)
US TECH 100
16,903.20
(
-0.77%
)
Dow Jones
37,775.38
(
0.06%
)
Brent Oil
88.93
(
2.90%
)
Bitcoin
61,127.04
(
-3.75%
)
Post# of 4273
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

iandy

Send PM Follow Ignore
Followers 18
Posts 3165
Boards Moderated 0
Alias Born 06/09/2010

iandy

Re: None

Thursday, 10/12/2017 2:34:14 PM

Thursday, October 12, 2017 2:34:14 PM

Post# of 4273
ARDX - The company is touting best-in-class responder rates but from first look it looks like similar efficacy to Linzess & Trulance with worse diarrhea, flatuance, and withdrawal rates than Trulance.

>T3MPO-2 Safety Results
Tenapanor was well-tolerated, consistent with the experience across previous clinical trials. The only adverse events observed in more than two percent of patients in the tenapanor-treated group that were also greater than placebo were diarrhea (16.0% vs. 3.7%), flatulence (3.1% vs. 1.0%), nasopharyngitis (4.4% vs. 3.7%) and abdominal distension (3.4% vs. 0.3%). The placebo adjusted discontinuation rate due to diarrhea was 5.8 percent.<

https://finance.yahoo.com/news/ardelyxs-pivotal-phase-3-study-200200377.html
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up